Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study

BMC Nephrology

Research Article

Sitaram Vangala¹  Satvinder K. Dhaliwal¹  Jenny I. Shen²  Anjali B. Saxena³  Wolfgang C. Winkelmayer⁴ 

[1] Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., C-1 Annex, 90502, Torrance, CA, USA;Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA;Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA;Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA;Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA;

关键词: Peritoneal dialysis;    Renin angiotensin system blockers;    Angiotensin converting enzyme inhibitors;    Angiotensin receptor blockers;    Residual kidney function;   

DOI  :  10.1186/s12882-017-0616-4

 received in 2016-05-31, accepted in 2017-06-09,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundAlthough angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) have been shown to preserve residual kidney function in a select group of Asian patients undergoing continuous ambulatory peritoneal dialysis (PD) in two small randomized clinical trials, the effectiveness of these drugs has yet to be demonstrated in a more diverse population of patients with multiple comorbid conditions. We investigated the association between ACEI/ARB use and development of recorded anuria in a cohort of patients initiating PD in the U.S.MethodsWe conducted a retrospective observational cohort study using the US Renal Data System and electronic health records data from a large national dialysis provider. We identified adult patients who initiated PD from 2007 to 2011. Only patients who participated in the federal prescription drug benefit program, Medicare Part D, for the first 90 days of dialysis were included. Patients who filled a prescription for an ACEI or ARB during those 90 days were considered users. We applied Cox proportional hazards models to an inverse probability of treatment-weighted (IPTW) cohort to estimate the hazard ratio (HR) for anuria (24-h urine volume < 200 ml) in ACEI/ARB users vs. non-users.ResultsAmong 886 patients, 389 (44%) used an ACEI/ARB. Almost a third of these patients were black or Hispanic, and more than a quarter had comorbidities that would have excluded them from the randomized clinical trials of ACEI/ARB. Two hundred eighty patients reached anuria over 840 person-years of follow-up, for a composite event rate of 33 events per 100 person-years. We found no clear association between ACEI/ARB use and progression to anuria [HR: 0.86, 95% CI: 0.73–1.02].ConclusionsACEI/ARB use is common in patients initiating PD in the U.S. but was not associated with a lower risk of anuria. Residual confounding by unmeasured variables is an important limitation of this observational study. Still, these findings suggest that pragmatic clinical trials are warranted to test the effectiveness of ACEI/ARB in slowing the decline of residual kidney function in a diverse population of peritoneal dialysis patients with multiple comorbid conditions.

【 授权许可】

CC BY   
© The Author(s). 2017